HLB Life Science CO.,LTD.
KOSDAQ
₩2,515.00
-1.37%
Delayed · cached 15 min
Price Chart
Price50-day avg200-day avg
How to read this: the line is the closing price over time. The two dashed lines are moving averages — the average price over the last 50 and 200 trading days — which smooth out daily noise to show the broader trend. Price above its moving averages reflects recent strength; below reflects recent weakness. Use the buttons to change the time range. Prices are end-of-day, not live.
✓Strengths
- Moderate debt: debt-to-equity of 0.61.
!Watch-points
- Thin interest cover: operating profit covers interest only about -0.3 times.
- Return on equity is on the lower side at -33.6%.
- Return on capital employed is on the lower side at -6.1%.
- The company reported a net loss in the latest period.
- Current ratio of 0.58 is below 1, so current liabilities exceed current assets.
- Sales growth has been slow over five years (about -14% a year).
These points are generated automatically from the company’s reported figures to highlight what stands out. They are descriptive observations for educational purposes only — not advice or a recommendation to buy, sell, or hold.
Forensic Checks
Altman Z-ScoreDistress zone
-0.43
In Altman’s study, scores in this range were associated with a higher incidence of financial distress.
Computed without the market-value term.
Piotroski F-ScoreWeak
0 / 5
The F-Score adds one point for each of several year-on-year signs of improving profitability, lower leverage and better efficiency. Higher is generally stronger.
Based on 5 of the 9 signals — the rest need data not available for this stock.
These are well-known academic screening models, shown for educational context only. They describe historical financial patterns and are not predictions, advice, or a recommendation to buy, sell, or hold.
Key Ratios
Market Cap₩3,064억
Current Price₩ 2,515.00
High / Low₩ 5,330.00 / 1,608.00
Stock P/E-3.07
Book Value₩ 2,440.36
ROCE-6.13%
ROE-33.56%
Debt to Equity0.61
Current Ratio0.58
EPS₩ -819.01
PAT Margin-218.45%
ICR-0.29
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity